Acute TrkB inhibition rescues phenobarbital-resistant seizures in a mouse model of neonatal ischemia

S. K. Kang, Michael V Johnston, S. D. Kadam

Research output: Contribution to journalArticle

Abstract

Neonatal seizures are commonly associated with hypoxic-ischemic encephalopathy. Phenobarbital (PB) resistance is common and poses a serious challenge in clinical management. Using a newly characterized neonatal mouse model of ischemic seizures, this study investigated a novel strategy for rescuing PB resistance. A small-molecule TrkB antagonist, ANA12, used to selectively and transiently block post-ischemic BDNF-TrkB signaling in vivo, determined whether rescuing TrkB-mediated post-ischemic degradation of the K+-Cl- co-transporter (KCC2) rescued PB-resistant seizures. The anti-seizure efficacy of ANA12 + PB was quantified by (i) electrographic seizure burden using acute continuous video-electroencephalograms and (ii) post-treatment expression levels of KCC2 and NKCC1 using Western blot analysis in postnatal day (P)7 and P10 CD1 pups with unilateral carotid ligation. ANA12 significantly rescued PB-resistant seizures at P7 and improved PB efficacy at P10. A single dose of ANA12 + PB prevented the post-ischemic degradation of KCC2 for up to 24 h. As anticipated, ANA12 by itself had no anti-seizure properties and was unable to prevent KCC2 degradation at 24 h without follow-on PB. This indicates that unsubdued seizures can independently lead to KCC2 degradation via non-TrkB-dependent pathways. This study, for the first time as a proof-of-concept, reports the potential therapeutic value of KCC2 modulation for the management of PB-resistant seizures in neonates. Future investigations are required to establish the mechanistic link between ANA12 and the prevention of KCC2 degradation.

Original languageEnglish (US)
Pages (from-to)2792-2804
Number of pages13
JournalEuropean Journal of Neuroscience
Volume42
Issue number10
DOIs
StatePublished - Nov 1 2015

Fingerprint

Phenobarbital
Seizures
Ischemia
Symporters
Brain Hypoxia-Ischemia
Brain-Derived Neurotrophic Factor
Ligation
Electroencephalography
Western Blotting

Keywords

  • Bumetanide
  • Hypoxic-ischemic encephalopathy
  • KCC2
  • Neonatal seizure
  • PB resistance

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Acute TrkB inhibition rescues phenobarbital-resistant seizures in a mouse model of neonatal ischemia. / Kang, S. K.; Johnston, Michael V; Kadam, S. D.

In: European Journal of Neuroscience, Vol. 42, No. 10, 01.11.2015, p. 2792-2804.

Research output: Contribution to journalArticle

@article{a8ba5fe2c1ed4526b87855481c2ec586,
title = "Acute TrkB inhibition rescues phenobarbital-resistant seizures in a mouse model of neonatal ischemia",
abstract = "Neonatal seizures are commonly associated with hypoxic-ischemic encephalopathy. Phenobarbital (PB) resistance is common and poses a serious challenge in clinical management. Using a newly characterized neonatal mouse model of ischemic seizures, this study investigated a novel strategy for rescuing PB resistance. A small-molecule TrkB antagonist, ANA12, used to selectively and transiently block post-ischemic BDNF-TrkB signaling in vivo, determined whether rescuing TrkB-mediated post-ischemic degradation of the K+-Cl- co-transporter (KCC2) rescued PB-resistant seizures. The anti-seizure efficacy of ANA12 + PB was quantified by (i) electrographic seizure burden using acute continuous video-electroencephalograms and (ii) post-treatment expression levels of KCC2 and NKCC1 using Western blot analysis in postnatal day (P)7 and P10 CD1 pups with unilateral carotid ligation. ANA12 significantly rescued PB-resistant seizures at P7 and improved PB efficacy at P10. A single dose of ANA12 + PB prevented the post-ischemic degradation of KCC2 for up to 24 h. As anticipated, ANA12 by itself had no anti-seizure properties and was unable to prevent KCC2 degradation at 24 h without follow-on PB. This indicates that unsubdued seizures can independently lead to KCC2 degradation via non-TrkB-dependent pathways. This study, for the first time as a proof-of-concept, reports the potential therapeutic value of KCC2 modulation for the management of PB-resistant seizures in neonates. Future investigations are required to establish the mechanistic link between ANA12 and the prevention of KCC2 degradation.",
keywords = "Bumetanide, Hypoxic-ischemic encephalopathy, KCC2, Neonatal seizure, PB resistance",
author = "Kang, {S. K.} and Johnston, {Michael V} and Kadam, {S. D.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1111/ejn.13094",
language = "English (US)",
volume = "42",
pages = "2792--2804",
journal = "European Journal of Neuroscience",
issn = "0953-816X",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Acute TrkB inhibition rescues phenobarbital-resistant seizures in a mouse model of neonatal ischemia

AU - Kang, S. K.

AU - Johnston, Michael V

AU - Kadam, S. D.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Neonatal seizures are commonly associated with hypoxic-ischemic encephalopathy. Phenobarbital (PB) resistance is common and poses a serious challenge in clinical management. Using a newly characterized neonatal mouse model of ischemic seizures, this study investigated a novel strategy for rescuing PB resistance. A small-molecule TrkB antagonist, ANA12, used to selectively and transiently block post-ischemic BDNF-TrkB signaling in vivo, determined whether rescuing TrkB-mediated post-ischemic degradation of the K+-Cl- co-transporter (KCC2) rescued PB-resistant seizures. The anti-seizure efficacy of ANA12 + PB was quantified by (i) electrographic seizure burden using acute continuous video-electroencephalograms and (ii) post-treatment expression levels of KCC2 and NKCC1 using Western blot analysis in postnatal day (P)7 and P10 CD1 pups with unilateral carotid ligation. ANA12 significantly rescued PB-resistant seizures at P7 and improved PB efficacy at P10. A single dose of ANA12 + PB prevented the post-ischemic degradation of KCC2 for up to 24 h. As anticipated, ANA12 by itself had no anti-seizure properties and was unable to prevent KCC2 degradation at 24 h without follow-on PB. This indicates that unsubdued seizures can independently lead to KCC2 degradation via non-TrkB-dependent pathways. This study, for the first time as a proof-of-concept, reports the potential therapeutic value of KCC2 modulation for the management of PB-resistant seizures in neonates. Future investigations are required to establish the mechanistic link between ANA12 and the prevention of KCC2 degradation.

AB - Neonatal seizures are commonly associated with hypoxic-ischemic encephalopathy. Phenobarbital (PB) resistance is common and poses a serious challenge in clinical management. Using a newly characterized neonatal mouse model of ischemic seizures, this study investigated a novel strategy for rescuing PB resistance. A small-molecule TrkB antagonist, ANA12, used to selectively and transiently block post-ischemic BDNF-TrkB signaling in vivo, determined whether rescuing TrkB-mediated post-ischemic degradation of the K+-Cl- co-transporter (KCC2) rescued PB-resistant seizures. The anti-seizure efficacy of ANA12 + PB was quantified by (i) electrographic seizure burden using acute continuous video-electroencephalograms and (ii) post-treatment expression levels of KCC2 and NKCC1 using Western blot analysis in postnatal day (P)7 and P10 CD1 pups with unilateral carotid ligation. ANA12 significantly rescued PB-resistant seizures at P7 and improved PB efficacy at P10. A single dose of ANA12 + PB prevented the post-ischemic degradation of KCC2 for up to 24 h. As anticipated, ANA12 by itself had no anti-seizure properties and was unable to prevent KCC2 degradation at 24 h without follow-on PB. This indicates that unsubdued seizures can independently lead to KCC2 degradation via non-TrkB-dependent pathways. This study, for the first time as a proof-of-concept, reports the potential therapeutic value of KCC2 modulation for the management of PB-resistant seizures in neonates. Future investigations are required to establish the mechanistic link between ANA12 and the prevention of KCC2 degradation.

KW - Bumetanide

KW - Hypoxic-ischemic encephalopathy

KW - KCC2

KW - Neonatal seizure

KW - PB resistance

UR - http://www.scopus.com/inward/record.url?scp=84954453447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954453447&partnerID=8YFLogxK

U2 - 10.1111/ejn.13094

DO - 10.1111/ejn.13094

M3 - Article

C2 - 26452067

AN - SCOPUS:84954453447

VL - 42

SP - 2792

EP - 2804

JO - European Journal of Neuroscience

JF - European Journal of Neuroscience

SN - 0953-816X

IS - 10

ER -